Compare Cadence Design Systems Inc (CDNS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs TG Therapeutics Inc — how do they compare? Cadence Design Systems Inc trades at $323.45 (market cap $90.20B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Cadence Design Systems Inc is far larger — about 11.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| CDNS | TGTX | |
|---|---|---|
Market Cap | $90.20B | $7.64B |
Sector | Technology | Health |
52-Week High | $416.39 | $59.06 |
52-Week Low | $265.66 | $26.94 |
Enterprise Value | $91.41B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $322.68, down 2.78% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 24.2% revenue growth in Q2 2026, a net income margin of 23.61%, and consistent earnings beats. Analyst consensus is bullish with a $415.11 price target, supported by AI-driven demand boosting backlog to $8.1 billion.
Outlook remains positive due to robust AI adoption and raised 2026 guidance, but risks include high valuation multiples and market volatility. The stock offers growth potential, though investors should monitor competitive pressures and execution risks in the semiconductor design software sector.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
